AI Article Synopsis
- - Talquetamab has been approved for treating relapsed refractory multiple myeloma, but data on patient outcomes with BCMA-based therapies after progression on talquetamab is lacking.
- - A study of 10 patients showed a median follow-up of 9.5 months and a median progression-free survival of 5.5 months after switching to BCMA therapies.
- - The study indicated that while adverse effects like cytokine release syndrome and neurotoxicity were present, using talquetamab followed by BCMA therapies is a feasible treatment option.
Article Abstract
Talquetamab recently received approval for relapsed refractory multiple myeloma. However, there is currently no available data on how patients perform with BCMA based agents after progression on talquetamab. Herein, we present the outcome of 10 patients who received BCMA based therapies following talquetamab. The median follow-up was 9.5 months (range: 6-24 months). The median progression free survival was 5.5 months (range: 1-10 months). Patients had varying grades of cytokine release syndrome and Immune effector cell-associated neurotoxicity syndrome. Our results suggest that treatment with talquetamab followed by BCMA based therapies is feasible and can be considered as clinically indicated.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11182413 | PMC |
| http://dx.doi.org/10.1002/jha2.896 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!